Various studies have been conducted to determine the efficacy of adjuvant therapy in stage II and III colon cancer using circulating tumor DNA as a marker for recurrence risk and benefit of treatment. Studies have shown promising results in tracking minimal residual disease and determining the need for adjuvant therapy in nonmetastatic colorectal cancer.